These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

685 related items for PubMed ID: 27079334

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
    Faggioni M, Baber U, Sartori S, Giustino G, Cohen DJ, Henry TD, Farhan S, Ariti C, Dangas G, Gibson M, Giacoppo D, Krucoff MW, Aquino M, Chandrasekhar J, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R.
    JACC Cardiovasc Interv; 2017 Apr 10; 10(7):645-654. PubMed ID: 28330641
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    Kirtane AJ, Parikh PB, Stuckey TD, Xu K, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Mazzaferri EL, Parvataneni R, Maehara A, Généreux P, Mehran R, Stone GW.
    JACC Cardiovasc Interv; 2015 Dec 28; 8(15):1978-1987. PubMed ID: 26738669
    [Abstract] [Full Text] [Related]

  • 6. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Yu J, Mehran R, Baber U, Ooi SY, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Brodie BR, Stuckey TD, Maehara A, Xu K, Ben-Yehuda O, Kirtane AJ, Stone GW.
    Circ Cardiovasc Interv; 2017 Feb 28; 10(2):. PubMed ID: 28193677
    [Abstract] [Full Text] [Related]

  • 7. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW, Kang SH, Park JJ, Yang HM, Kang HJ, Koo BK, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Chae IH, Kim HS.
    JACC Cardiovasc Interv; 2013 Sep 28; 6(9):932-42. PubMed ID: 24050860
    [Abstract] [Full Text] [Related]

  • 8. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G, Rossini R, Lettieri C, Capodanno D, Romano M, Rosiello R, Guagliumi G, Valsecchi O, Gavazzi A, Angiolillo DJ.
    Catheter Cardiovasc Interv; 2012 Sep 01; 80(3):395-405. PubMed ID: 22109961
    [Abstract] [Full Text] [Related]

  • 9. The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
    Brener SJ, Kirtane AJ, Stuckey TD, Witzenbichler B, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Mehran R, Parvataneni R, Brodie BR, Stone GW.
    JACC Cardiovasc Interv; 2016 Jul 25; 9(14):1450-7. PubMed ID: 27372190
    [Abstract] [Full Text] [Related]

  • 10. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
    Baber U, Leisman DE, Cohen DJ, Gibson CM, Henry TD, Dangas G, Moliterno D, Kini A, Krucoff M, Colombo A, Chieffo A, Sartori S, Witzenbichler B, Steg PG, Pocock SJ, Mehran R.
    Circ Cardiovasc Qual Outcomes; 2019 Jan 25; 12(1):e004945. PubMed ID: 30606052
    [Abstract] [Full Text] [Related]

  • 11. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    Stuckey TD, Kirtane AJ, Brodie BR, Witzenbichler B, Litherland C, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Gurbel PA, Mehran R, Généreux P, Ben-Yehuda O, Simonton CA, Stone GW, ADAPT-DES Investigators.
    JACC Cardiovasc Interv; 2017 Aug 28; 10(16):1607-1617. PubMed ID: 28780034
    [Abstract] [Full Text] [Related]

  • 12. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ, Nicolela EL, Perin MA, Devito FS, Labrunie A, Salvadori D, Gusmão M, Staico R, Costa JR, de Castro JP, Abizaid AS, Bhatt DL, OPTIMIZE Trial Investigators.
    JAMA; 2013 Dec 18; 310(23):2510-22. PubMed ID: 24177257
    [Abstract] [Full Text] [Related]

  • 13. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J, Bansilal S, Baber U, Sartori S, Aquino M, Farhan S, Vogel B, Faggioni M, Giustino G, Ariti C, Colombo A, Chieffo A, Kini A, Saporito R, Michael Gibson C, Witzenbichler B, Cohen D, Moliterno D, Stuckey T, Henry T, Pocock S, Dangas G, Gabriel Steg P, Mehran R.
    Catheter Cardiovasc Interv; 2017 Jun 01; 89(7):E217-E225. PubMed ID: 27650638
    [Abstract] [Full Text] [Related]

  • 14. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R, Kirtane AJ, Ozan MO, Witzenbichler B, Rinaldi MJ, Metzger DC, Weisz G, Stuckey TD, Brodie BR, Mehran R, Ben-Yehuda O, Stone GW.
    Circ Cardiovasc Interv; 2017 Mar 01; 10(3):. PubMed ID: 28288963
    [Abstract] [Full Text] [Related]

  • 15. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    Gargiulo G, Ariotti S, Santucci A, Piccolo R, Baldo A, Franzone A, Magnani G, Marino M, Esposito G, Windecker S, Valgimigli M.
    JACC Cardiovasc Interv; 2016 Sep 12; 9(17):1780-9. PubMed ID: 27544007
    [Abstract] [Full Text] [Related]

  • 16. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry.
    Baber U, Dangas G, Chandrasekhar J, Sartori S, Steg PG, Cohen DJ, Giustino G, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, Moliterno DJ, Weisz G, Colombo A, Pocock S, Mehran R.
    JACC Cardiovasc Interv; 2016 Jul 11; 9(13):1349-57. PubMed ID: 27388822
    [Abstract] [Full Text] [Related]

  • 17. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
    Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB, Massaro JM, Hsieh WH, Mauri L, DAPT Investigators.
    Circulation; 2017 May 02; 135(18):1720-1732. PubMed ID: 28228427
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ, Dufour AB, Cho K, Gagnon DR, Quach L, Ly S, Do JM, Ostrowski S, Michael Gaziano J, Faxon DP, Kinlay S.
    Catheter Cardiovasc Interv; 2017 Jun 01; 89(7):1176-1184. PubMed ID: 27860195
    [Abstract] [Full Text] [Related]

  • 19. Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study).
    Redfors B, Ben-Yehuda O, Lin SH, Furer A, Kirtane AJ, Witzenbichler B, Weisz G, Stuckey TD, Maehara A, Généreux P, Giustino G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Ayele GM, Mehran R, Mintz GS, Stone GW.
    Am J Cardiol; 2017 Sep 15; 120(6):917-923. PubMed ID: 28754568
    [Abstract] [Full Text] [Related]

  • 20. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry.
    Moalem K, Baber U, Chandrasekhar J, Claessen BE, Sartori S, Aquino M, Dangas G, Iakovou I, Colombo A, Kini A, Gibson M, Krucoff M, Chieffo A, Moliterno D, Witzenbichler B, Pocock S, Mehran R.
    Clin Res Cardiol; 2019 Jun 15; 108(6):643-650. PubMed ID: 30607496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.